vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and OFG BANCORP (OFG). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $184.3M, roughly 1.5× OFG BANCORP). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 30.3%, a 66.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 0.9%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 2.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
ACAD vs OFG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $184.3M |
| Net Profit | $273.6M | $55.9M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 25.7% |
| Net Margin | 96.3% | 30.3% |
| Revenue YoY | 9.4% | 0.9% |
| Net Profit YoY | 90.3% | 11.0% |
| EPS (diluted) | $1.61 | $1.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $184.3M | ||
| Q3 25 | $278.6M | $186.2M | ||
| Q2 25 | $264.6M | $182.4M | ||
| Q1 25 | $244.3M | $178.6M | ||
| Q4 24 | $259.6M | $182.7M | ||
| Q3 24 | $250.4M | $174.7M | ||
| Q2 24 | $242.0M | $179.8M | ||
| Q1 24 | $205.8M | $174.4M |
| Q4 25 | $273.6M | $55.9M | ||
| Q3 25 | $71.8M | $51.8M | ||
| Q2 25 | $26.7M | $51.8M | ||
| Q1 25 | $19.0M | $45.6M | ||
| Q4 24 | $143.7M | $50.3M | ||
| Q3 24 | $32.8M | $47.0M | ||
| Q2 24 | $33.4M | $51.1M | ||
| Q1 24 | $16.6M | $49.7M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 25.7% | ||
| Q3 25 | 12.8% | 33.0% | ||
| Q2 25 | 12.2% | 36.1% | ||
| Q1 25 | 7.9% | 33.3% | ||
| Q4 24 | 59.1% | 28.9% | ||
| Q3 24 | 12.6% | 35.4% | ||
| Q2 24 | 12.6% | 39.6% | ||
| Q1 24 | 7.4% | 38.9% |
| Q4 25 | 96.3% | 30.3% | ||
| Q3 25 | 25.8% | 27.8% | ||
| Q2 25 | 10.1% | 28.4% | ||
| Q1 25 | 7.8% | 25.5% | ||
| Q4 24 | 55.4% | 27.6% | ||
| Q3 24 | 13.1% | 26.9% | ||
| Q2 24 | 13.8% | 28.4% | ||
| Q1 24 | 8.0% | 28.5% |
| Q4 25 | $1.61 | $1.27 | ||
| Q3 25 | $0.42 | $1.16 | ||
| Q2 25 | $0.16 | $1.15 | ||
| Q1 25 | $0.11 | $1.00 | ||
| Q4 24 | $0.86 | $1.10 | ||
| Q3 24 | $0.20 | $1.00 | ||
| Q2 24 | $0.20 | $1.08 | ||
| Q1 24 | $0.10 | $1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $1.0B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.4B |
| Total Assets | $1.6B | $12.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $1.0B | ||
| Q3 25 | $258.0M | $740.3M | ||
| Q2 25 | $253.6M | $851.8M | ||
| Q1 25 | $217.7M | $710.6M | ||
| Q4 24 | $319.6M | $591.1M | ||
| Q3 24 | $155.1M | $680.6M | ||
| Q2 24 | $177.1M | $740.4M | ||
| Q1 24 | $204.7M | $754.4M |
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $917.3M | $1.4B | ||
| Q2 25 | $822.4M | $1.3B | ||
| Q1 25 | $765.2M | $1.3B | ||
| Q4 24 | $732.8M | $1.3B | ||
| Q3 24 | $577.2M | $1.3B | ||
| Q2 24 | $516.7M | $1.2B | ||
| Q1 24 | $464.0M | $1.2B |
| Q4 25 | $1.6B | $12.5B | ||
| Q3 25 | $1.3B | $12.2B | ||
| Q2 25 | $1.2B | $12.2B | ||
| Q1 25 | $1.1B | $11.7B | ||
| Q4 24 | $1.2B | $11.5B | ||
| Q3 24 | $976.9M | $11.5B | ||
| Q2 24 | $914.1M | $11.3B | ||
| Q1 24 | $855.1M | $11.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $217.7M |
| Free Cash FlowOCF − Capex | — | $199.3M |
| FCF MarginFCF / Revenue | — | 108.1% |
| Capex IntensityCapex / Revenue | — | 10.0% |
| Cash ConversionOCF / Net Profit | -0.18× | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | — | $345.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $217.7M | ||
| Q3 25 | $74.3M | $39.5M | ||
| Q2 25 | $64.0M | $35.9M | ||
| Q1 25 | $20.3M | $83.1M | ||
| Q4 24 | $40.4M | $252.5M | ||
| Q3 24 | $63.2M | $58.1M | ||
| Q2 24 | $25.0M | $95.1M | ||
| Q1 24 | $29.1M | $61.0M |
| Q4 25 | — | $199.3M | ||
| Q3 25 | $73.9M | $35.5M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $78.7M | ||
| Q4 24 | — | $231.2M | ||
| Q3 24 | $63.2M | $51.8M | ||
| Q2 24 | — | $90.4M | ||
| Q1 24 | — | $54.8M |
| Q4 25 | — | 108.1% | ||
| Q3 25 | 26.5% | 19.1% | ||
| Q2 25 | — | 17.4% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | — | 126.5% | ||
| Q3 24 | 25.2% | 29.6% | ||
| Q2 24 | — | 50.3% | ||
| Q1 24 | — | 31.4% |
| Q4 25 | — | 10.0% | ||
| Q3 25 | 0.1% | 2.1% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 0.0% | 3.6% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | -0.18× | 3.90× | ||
| Q3 25 | 1.03× | 0.76× | ||
| Q2 25 | 2.40× | 0.69× | ||
| Q1 25 | 1.07× | 1.82× | ||
| Q4 24 | 0.28× | 5.02× | ||
| Q3 24 | 1.93× | 1.24× | ||
| Q2 24 | 0.75× | 1.86× | ||
| Q1 24 | 1.76× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
OFG
Segment breakdown not available.
